AR005930A1 - Genes hiv sinteticos, composiciones de vacunas relacionadas y metodo para aumentar la expresion de adn - Google Patents
Genes hiv sinteticos, composiciones de vacunas relacionadas y metodo para aumentar la expresion de adnInfo
- Publication number
- AR005930A1 AR005930A1 ARP970100684A ARP970100684A AR005930A1 AR 005930 A1 AR005930 A1 AR 005930A1 AR P970100684 A ARP970100684 A AR P970100684A AR P970100684 A ARP970100684 A AR P970100684A AR 005930 A1 AR005930 A1 AR 005930A1
- Authority
- AR
- Argentina
- Prior art keywords
- vaccine compositions
- dna expression
- hiv genes
- synthetic hiv
- increasing dna
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/67—General methods for enhancing the expression
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Communicable Diseases (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- AIDS & HIV (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Se proveen moléculas de ADN sintéticas que codifican genes de HIV y modificaciones de genes de HIV. Los codones de las moléculas sintéticas usancodones preferidos para la célula huésped proyectada. Las moléculas sintéticas pueden usarse en forma de una vacuna polinucleotídica que proveeinmunoprofilaxis eficaz contra infección causada por HIV a través de un anticuerpo neutralizador e inmunidad intermediada por células.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US1208296P | 1996-02-22 | 1996-02-22 | |
GBGB9607293.9A GB9607293D0 (en) | 1996-04-09 | 1996-04-09 | Synthetic hiv env genes |
Publications (1)
Publication Number | Publication Date |
---|---|
AR005930A1 true AR005930A1 (es) | 1999-07-21 |
Family
ID=26309076
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP970100684A AR005930A1 (es) | 1996-02-22 | 1997-02-20 | Genes hiv sinteticos, composiciones de vacunas relacionadas y metodo para aumentar la expresion de adn |
Country Status (27)
Country | Link |
---|---|
EP (1) | EP0904380B1 (es) |
JP (1) | JP2000505299A (es) |
KR (1) | KR19990087126A (es) |
CN (1) | CN1216064A (es) |
AR (1) | AR005930A1 (es) |
AT (1) | ATE309366T1 (es) |
AU (1) | AU729231B2 (es) |
BG (1) | BG102784A (es) |
BR (1) | BR9707672A (es) |
CO (1) | CO4600706A1 (es) |
CZ (1) | CZ266798A3 (es) |
DE (1) | DE69734585T2 (es) |
EE (1) | EE9800257A (es) |
ES (1) | ES2251734T3 (es) |
HR (1) | HRP970092A2 (es) |
HU (1) | HUP9901112A3 (es) |
ID (1) | ID16021A (es) |
IL (1) | IL125547A0 (es) |
IS (1) | IS4814A (es) |
NO (1) | NO983876L (es) |
NZ (1) | NZ331161A (es) |
PE (1) | PE43298A1 (es) |
PL (1) | PL328730A1 (es) |
SK (1) | SK112998A3 (es) |
TR (1) | TR199801615T2 (es) |
WO (1) | WO1997031115A2 (es) |
YU (1) | YU35498A (es) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6534312B1 (en) | 1996-02-22 | 2003-03-18 | Merck & Co., Inc. | Vaccines comprising synthetic genes |
EP0912607A2 (en) * | 1996-06-21 | 1999-05-06 | Merck & Co., Inc. | Vaccines comprising synthetic genes |
US6696291B2 (en) | 1997-02-07 | 2004-02-24 | Merck & Co., Inc. | Synthetic HIV gag genes |
ES2274566T3 (es) * | 1997-02-07 | 2007-05-16 | MERCK & CO., INC. | Genes gag del vih sinteticos. |
JP2001519663A (ja) | 1997-04-04 | 2001-10-23 | ピー. ウィークス、ドナルド | 遺伝子導入ジカンバ−分解生物体を製造及び使用するための方法及び材料 |
US7105724B2 (en) | 1997-04-04 | 2006-09-12 | Board Of Regents Of University Of Nebraska | Methods and materials for making and using transgenic dicamba-degrading organisms |
AU2003200914B2 (en) * | 1997-10-20 | 2007-02-01 | Gtc Biotherapeutics, Inc. | Novel modified nucleic acid sequences and methods for increasing mRNA levels and protein expression in cell systems |
US6593463B1 (en) | 1997-10-20 | 2003-07-15 | Genzyme Transgenics Corporation | Modified MSP-1 nucleic acid sequences and methods for increasing MRNA levels and protein expression in cell systems |
GB9803351D0 (en) | 1998-02-17 | 1998-04-15 | Oxford Biomedica Ltd | Anti-viral vectors |
US6924365B1 (en) | 1998-09-29 | 2005-08-02 | Transkaryotic Therapies, Inc. | Optimized messenger RNA |
US7935805B1 (en) | 1998-12-31 | 2011-05-03 | Novartis Vaccines & Diagnostics, Inc | Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof |
EP1535995A1 (en) * | 1998-12-31 | 2005-06-01 | Chiron Corporation | Polynucleotides encoding the antigenic HIV type C env polypeptide and uses thereof |
CA2360347C (en) * | 1998-12-31 | 2013-05-07 | Chiron Corporation | Improved expression of hiv polypeptides and production of virus-like particles |
EP1433851A3 (en) * | 1998-12-31 | 2004-10-13 | Chiron Corporation | Improved expression of HIV polypeptides and production of virus-like particles |
EP1141314A2 (en) * | 1998-12-31 | 2001-10-10 | Chiron Corporation | Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof |
US6395714B1 (en) * | 1999-02-24 | 2002-05-28 | Aventis Pasteur Limited | Expressing gp140 fragment of primary HIV-1 isolate |
EP1165798A2 (en) | 1999-03-29 | 2002-01-02 | Statens Serum Institut | Nucleotide construct with optimised codons for an hiv genetic vaccine based on a primary, early hiv isolate and synthetic envelope |
US8647864B2 (en) | 1999-04-14 | 2014-02-11 | Novartis Ag | Compositions and methods for generating an immune response utilizing alphavirus-based vector systems |
EP1200622A4 (en) | 1999-07-06 | 2004-12-22 | Merck & Co Inc | HIV VACCINE COMPRISING A GAG GENE VEHICLE ADENOVIRUS |
US6316253B1 (en) | 1999-11-01 | 2001-11-13 | Chiron Corporation | Expression vectors, transfection systems, and method of use thereof |
CA2395429A1 (en) * | 1999-12-22 | 2001-06-28 | Merck & Co., Inc. | Polynucleotide vaccines expressing codon optimized hiv-1 pol and modified hiv-1 pol |
GB0014288D0 (en) | 2000-06-10 | 2000-08-02 | Smithkline Beecham Biolog | Vaccine |
GB0017990D0 (en) | 2000-07-21 | 2000-09-13 | Glaxo Group Ltd | Papilloma virus sequences |
US6733993B2 (en) | 2000-09-15 | 2004-05-11 | Merck & Co., Inc. | Enhanced first generation adenovirus vaccines expressing codon optimized HIV1-gag, pol, nef and modifications |
JP2004510714A (ja) * | 2000-10-04 | 2004-04-08 | ザ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルベニア | フラビウイルス及びペスチウイルス由来のキャプシド蛋白質を使用する組成物及び方法 |
KR20020059856A (ko) | 2001-01-08 | 2002-07-16 | 김철중 | 에이치아이브이 유사입자의 제조 |
AU2002320314A1 (en) | 2001-07-05 | 2003-01-21 | Chiron, Corporation | Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof |
PL207168B1 (pl) * | 2001-09-20 | 2010-11-30 | Glaxo Group Ltd | Sekwencja nukleotydowa, wektor, białko, środek farmaceutyczny, urządzenie do podawania śródskórnego, zastosowanie sekwencji nukleotydowej i sposób wytwarzania nukleotydu |
AU2004308964B2 (en) | 2003-12-23 | 2010-09-16 | Arbor Vita Corporation | Antibodies for oncogenic strains of HPV and methods of their use |
US7855326B2 (en) | 2006-06-06 | 2010-12-21 | Monsanto Technology Llc | Methods for weed control using plants having dicamba-degrading enzymatic activity |
AR063316A1 (es) | 2006-10-16 | 2009-01-21 | Monsanto Technology Llc | Metodos y composiciones para mejorar el estado sanitario de plantas |
US7838729B2 (en) | 2007-02-26 | 2010-11-23 | Monsanto Technology Llc | Chloroplast transit peptides for efficient targeting of DMO and uses thereof |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994016737A1 (en) * | 1993-01-26 | 1994-08-04 | Weiner David B | Compositions and methods for delivery of genetic material |
DE69536091D1 (de) * | 1994-01-27 | 2010-09-09 | Univ Massachusetts Medical | Immunisierung durch Impfung von DNS Transkriptionseinheit |
US6630455B1 (en) * | 1995-01-13 | 2003-10-07 | Vanderbilt University | Methods for inducing mucosal immune responses |
JPH08198774A (ja) * | 1995-01-20 | 1996-08-06 | Terumo Corp | Dnaワクチン |
-
1997
- 1997-02-18 HU HU9901112A patent/HUP9901112A3/hu unknown
- 1997-02-18 AU AU21246/97A patent/AU729231B2/en not_active Ceased
- 1997-02-18 TR TR1998/01615T patent/TR199801615T2/xx unknown
- 1997-02-18 BR BR9707672A patent/BR9707672A/pt unknown
- 1997-02-18 PL PL97328730A patent/PL328730A1/xx unknown
- 1997-02-18 WO PCT/US1997/002294 patent/WO1997031115A2/en active IP Right Grant
- 1997-02-18 ES ES97906594T patent/ES2251734T3/es not_active Expired - Lifetime
- 1997-02-18 NZ NZ331161A patent/NZ331161A/xx unknown
- 1997-02-18 CN CN97193817A patent/CN1216064A/zh active Pending
- 1997-02-18 AT AT97906594T patent/ATE309366T1/de not_active IP Right Cessation
- 1997-02-18 SK SK1129-98A patent/SK112998A3/sk unknown
- 1997-02-18 CZ CZ982667A patent/CZ266798A3/cs unknown
- 1997-02-18 EP EP97906594A patent/EP0904380B1/en not_active Expired - Lifetime
- 1997-02-18 EE EE9800257A patent/EE9800257A/xx unknown
- 1997-02-18 HR HR9607293.9A patent/HRP970092A2/hr not_active Application Discontinuation
- 1997-02-18 KR KR1019980706517A patent/KR19990087126A/ko not_active Application Discontinuation
- 1997-02-18 IL IL12554797A patent/IL125547A0/xx unknown
- 1997-02-18 JP JP9530231A patent/JP2000505299A/ja not_active Ceased
- 1997-02-18 DE DE69734585T patent/DE69734585T2/de not_active Expired - Fee Related
- 1997-02-20 AR ARP970100684A patent/AR005930A1/es unknown
- 1997-02-21 ID IDP970514A patent/ID16021A/id unknown
- 1997-02-21 PE PE1997000126A patent/PE43298A1/es not_active Application Discontinuation
- 1997-02-21 CO CO97009327A patent/CO4600706A1/es unknown
-
1998
- 1998-07-30 IS IS4814A patent/IS4814A/is unknown
- 1998-08-21 YU YU35498A patent/YU35498A/sh unknown
- 1998-08-21 NO NO983876A patent/NO983876L/no not_active Application Discontinuation
- 1998-09-23 BG BG102784A patent/BG102784A/xx unknown
Also Published As
Publication number | Publication date |
---|---|
CZ266798A3 (cs) | 1999-03-17 |
CN1216064A (zh) | 1999-05-05 |
YU35498A (sh) | 1999-07-28 |
PL328730A1 (en) | 1999-02-15 |
WO1997031115A2 (en) | 1997-08-28 |
CO4600706A1 (es) | 1998-05-08 |
BG102784A (en) | 1999-05-31 |
ATE309366T1 (de) | 2005-11-15 |
ES2251734T3 (es) | 2006-05-01 |
IS4814A (is) | 1998-07-30 |
PE43298A1 (es) | 1998-08-29 |
IL125547A0 (en) | 1999-03-12 |
KR19990087126A (ko) | 1999-12-15 |
SK112998A3 (en) | 2000-04-10 |
AU2124697A (en) | 1997-09-10 |
DE69734585T2 (de) | 2006-08-10 |
EP0904380B1 (en) | 2005-11-09 |
WO1997031115A3 (en) | 1997-10-09 |
ID16021A (id) | 1997-08-28 |
NZ331161A (en) | 2000-03-27 |
HUP9901112A2 (hu) | 1999-07-28 |
AU729231B2 (en) | 2001-01-25 |
HUP9901112A3 (en) | 2001-06-28 |
EP0904380A2 (en) | 1999-03-31 |
JP2000505299A (ja) | 2000-05-09 |
EE9800257A (et) | 1999-02-15 |
HRP970092A2 (en) | 1998-04-30 |
BR9707672A (pt) | 1999-04-13 |
NO983876L (no) | 1998-10-21 |
DE69734585D1 (de) | 2005-12-15 |
NO983876D0 (no) | 1998-08-21 |
TR199801615T2 (xx) | 1998-11-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR005930A1 (es) | Genes hiv sinteticos, composiciones de vacunas relacionadas y metodo para aumentar la expresion de adn | |
DK0969862T3 (da) | Syntetisk HIV gag-gener | |
PT1212358E (pt) | Genes sinteticos de papilomavirus humano | |
AR059828A2 (es) | Formula de vacuna para equidos, su utilizacion y kit de vacunacion | |
ES2151506T3 (es) | Moleculas de adn recombinante que codifican enzimas aminopeptidasa y su uso en la preparacion de vacunas contra infecciones por helmintos. | |
DE69925618D1 (de) | Rna krebsimpfstoff und verfahren zu dessen benutzung | |
WO2003059381A3 (en) | Immunogenic preparations and vaccines on the basis of mrna | |
CO5070644A1 (es) | Vacunas que comprenden proteinas e6 de hpv y/o e7 de hpv junto con un oligonucleotido cpg como adyudante | |
CO5360638A1 (es) | Un cepillo de dientes con cerdas individualmente embebidas | |
ES2173314T3 (es) | Metodos y composiciones para la modificacion selectiva de acidos nucleicos. | |
ES2070866T3 (es) | Vacunas recombinantes contra la coccidiosis. | |
AR011527A1 (es) | Metodo para mejorar la eficiencia de la transformacion | |
AR024771A1 (es) | Genes y vacunas efectivas contra la calicivirosis felina, en particular vacunas recombinantes | |
ES2194024T3 (es) | Una proteina de de superficie celular, denominada proteina rib, que confiere inmunidad a muchas cepas de estreptococos del grupo b; procedimiento para purificar la proteina, kit de reactivos y composicion farmaceutica. | |
ES2146214T3 (es) | Vacunas para actinobacillus pleuropneumoniae. | |
ES2192559T3 (es) | Vacuna para la proteccion de aves de corral contra la coccidiosis. | |
PT1272652E (pt) | Virus de herpes para a modulacao imunitaria | |
ECSP972034A (es) | Genes sinteticos vih | |
ES2059305T3 (es) | Proteina del virus de la seudorrabia. | |
AR022662A1 (es) | Acidos nucleicos y proteinas del gen mhp3 de mycoplasma hyopneumoniae y sus usos | |
ES2166763T3 (es) | Inmunizacion parenteral contra rotavirus. | |
ES2132050T1 (es) | Proceso para separar diclorodifluorometano. | |
BR0013574A (pt) | Antìgeno vacina de moraxella | |
EA199800750A1 (ru) | Синтетические гены вич | |
PT980379E (pt) | Oligonucleotidos quimericos e sua utilizacao |